{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=124", "query": { "condition": "Lymphoma", "page": 124 }, "page_size": 10 }, "pagination": { "page": 124, "page_size": 10, "total_count": 5761, "total_pages": 577, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=125&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=123&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-10T22:00:52.303Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07763210", "title": "Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Marginal Zone Lymphoma" ], "interventions": [ { "name": "Therapeutic Hydrocortisone", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Axicabtagene Ciloleucel", "type": "BIOLOGICAL" }, { "name": "Brexucabtagene Autoleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2026-09-25", "completion_date": "2029-10-01", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-11-10T22:00:52.303Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07763210" }, { "nct_id": "NCT01593696", "title": "Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ALL", "B Cell Lymphoma", "Leukemia", "Large Cell Lymphoma", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 53, "start_date": "2012-06-29", "completion_date": "2017-10-02", "has_results": true, "last_update_posted_date": "2020-08-31", "last_synced_at": "2026-11-10T22:00:52.303Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01593696" }, { "nct_id": "NCT00036790", "title": "Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Colorectal Cancer", "Head and Neck Cancer", "Leukemia", "Lung Cancer", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic/Myeloproliferative Diseases", "Prostate Cancer", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "motexafin gadolinium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2002-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-11-10T22:00:52.303Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania • Madison, Wisconsin", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036790" }, { "nct_id": "NCT07015242", "title": "A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Procarbazine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Liso-cel", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Calcium folinate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2025-11-06", "completion_date": "2028-12-10", "has_results": false, "last_update_posted_date": "2026-11-05", "last_synced_at": "2026-11-10T22:00:52.303Z", "location_count": 14, "location_summary": "Aurora, Colorado • Tampa, Florida • Chicago, Illinois + 11 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07015242" }, { "nct_id": "NCT03952078", "title": "A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T-cell Lymphoma" ], "interventions": [ { "name": "CPI-818", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corvus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 151, "start_date": "2019-05-03", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-11-10T22:00:52.303Z", "location_count": 6, "location_summary": "Palo Alto, California • Ann Arbor, Michigan • St Louis, Missouri + 3 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03952078" }, { "nct_id": "NCT01309789", "title": "A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Large-Cell, Anaplastic", "Lymphoma, NK-cell", "Lymphoma, T-cell" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2011-02", "completion_date": "2017-02-28", "has_results": false, "last_update_posted_date": "2017-06-28", "last_synced_at": "2026-11-10T22:00:52.303Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Duarte, California • Stanford, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01309789" }, { "nct_id": "NCT05098613", "title": "Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin Lymphoma", "B-cell Non-Hodgkin Lymphoma (B-NHL)", "Mantle Cell Lymphoma (MCL)", "CNS Lymphoma" ], "interventions": [ { "name": "CD19x22 CAR T Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 68, "start_date": "2021-12-21", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-11-10T22:00:52.303Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05098613" }, { "nct_id": "NCT00134082", "title": "Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "KGEL vaccine", "type": "BIOLOGICAL" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 31, "start_date": "2005-11", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2019-02-26", "last_synced_at": "2026-11-10T22:00:52.303Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00134082" }, { "nct_id": "NCT00002725", "title": "Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "bryostatin 1", "type": "DRUG" }, { "name": "chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 35, "start_date": "1996-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-05", "last_synced_at": "2026-11-10T22:00:52.303Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002725" }, { "nct_id": "NCT05828589", "title": "A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Relapsed Chronic Lymphocytic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Relapsed Follicular Lymphoma", "Relapsed Marginal Zone Lymphoma", "Relapse Diffuse Large B Cell Lymphoma", "Relapsed Small Lymphocytic Lymphoma", "Refractory Follicular Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Small Lymphocytic Lymphoma", "Richter Transformation", "Refractory Diffuse Large B-cell Lymphoma", "Transformed Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "BGB-21447", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2023-06-20", "completion_date": "2026-06-08", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-11-10T22:00:52.303Z", "location_count": 7, "location_summary": "Washington D.C., District of Columbia • Iowa City, Iowa • Waukee, Iowa + 4 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Waukee", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Mineola", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05828589" } ] }